

Remarks/Argument

Claims 1-8 and 20-22 are pending in the application.

This is in further response to the office action mailed on May 20, 2003, and in response to the telephone conference with Examiner Audet of Sept. 15, 2003. No fee is believed due to support the filing of this paper. If a fee is due, the Commissioner is hereby authorized to charge Deposit Account 50-0573.

Examiner Audet indicated that claim 1 would not be allowed to the extent it recited a peptide of SEQ ID NO:28 or NO:29. That subject matter is cancelled from claim 1 without prejudice to the filing of a continuing application.

A typographical error has been corrected in claim 20 ("n" should be a subscript).

The sequence listing is amended to correct an inadvertent error in the listing of SEQ ID NO:2. In compiling the Sequence Listing, the amino acid sequence of SEQ ID NO:1 was inadvertently duplicated as SEQ ID NO:2. The correct amino acid sequence for SEQ ID NO:2 is set forth in the specification at page 17, line 20. Thus, the amendment to the Sequence Listing is supported by the specification.

Based on the foregoing, Applicants believe that all pending claims are in condition for allowance. An early and favorable action in this regard is earnestly solicited.

Respectfully submitted,

ZIWEI HUANG et al.

BY: 

DANIEL A. MONACO
Registration No. 30,480
Drinker Biddle & Reath LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
Tel: 215-988-3304
Fax: 215-988-2757
Attorney for Applicants